Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
As we have previously discussed, the question posed above is a highly controversial one, and there is a legal case in the U.S. — the case challenging Myriad Genetics ownership of patents on the BRCA1 and BRCA2 genes for specific types of breast cancer — which has now reached the Supreme Court (sometimes called SCOTUS [...]
Filed under: Diagnosis, Risk | Tagged: gene, Myriad Genetics, patent, Supreme Court | 3 Comments »
An article by Markert et al., just published on line in the Proceedings of the National Academy of Sciences, suggests that microarray analysis of messenger ribonucleic acid (mRNA) expression in prostate cancer tumors may be an independent indicator of the aggressiveness of prostate cancers in individual patients.
Filed under: Diagnosis, Management, Risk | Tagged: expression. signature, gene, mortality, outcome, profile, risk | 1 Comment »
According to a report in the Science section of the Financial Times, “the world’s first nationwide genetic testing programme for cancer patients goes into action in the UK next month, with support from the public, private and charitable sectors.”
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Diagnosis, expression, gene, genetics, Management, risk | Leave a Comment »
We lost count some time ago of the number of different single nucleotide polymorphism (SNPs) that had been “associated” in some way or other with risk for prostate cancer and/or with risk for more aggressive forms of prostate cancer in specific sets of people (e.g., Swedes, African-Americans, Ghanaians, Caucasians in general, you name it).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: gene, prognosis, risk, single nucleotide polymorphism, SNP | 1 Comment »
In March 2010, as previously reported on this web site, a federal court judge initially ruled that the patents on the BRCA1 and BRCA2 genes held by Myriad Genetics and the University of Utah “are directed to a law of nature and were therefore improperly granted.”
Filed under: Diagnosis, Management | Tagged: BRCA, gene, Myriad Genetics, patent | 1 Comment »
There has been a lot of media “chatter” over the past 3 days about an article published in the journal Cancer Research. The article suggests that an investigational genetic test can project the presence of prostate cancer in biopsy-based specimens with an average accuracy of 97 percent.
Filed under: Diagnosis, Risk | Tagged: Diagnosis, gene, genetics, profiling, risk | Leave a Comment »
One of the problems with the PSA test is that it identifies a possible risk for prostate cancer in many men each year who are subsequently shown — by prostate biopsy — to be at no risk for the actual clinical condition.
Filed under: Diagnosis, Risk | Tagged: biopsy, Diagnosis, gene, profiling, risk | Leave a Comment »
A team of researchers at the University of Michigan Comprehensive Cancer Center are claiming that they have identified an important target that may lead to the development of effective treatments for one aggressive type of prostate cancer. The target is a gene called SPINK1.
Filed under: Diagnosis, Risk | Tagged: aggressive, Diagnosis, gene, risk, SPINK1 | 2 Comments »
A new paper by a multi-center research team has refined the long-held suspicion that some types of aggressive prostate cancer may be the consequence of the accumulation of multiple mutations in the patients’ DNA.
Filed under: Diagnosis, Management, Risk | Tagged: Diagnosis, fusion, gene, risk | Leave a Comment »
If you just read the media reports (for example, from Reuters, from the BBC or from The Daily Telegraph) you might get the idea that a new urine-based test for a protein called MSMB is vastly better at detecting prostate cancer than the PSA test. Sorry, but that is not actually the case at all.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: gene, microseminoprotein-β, MSMB, risk | 1 Comment »
There is an interesting new paper forthcoming in the Journal of Urology in which the research team describes how the addition of data from genetic profiling is able to improve the accuracy of the Kattan pre-treatment nomogram specifically in men believed to have localized prostate cancer at the time of diagnosis.
Filed under: Diagnosis, Management, Risk, Uncategorized | Tagged: gene, Kattan, nomogram, pre-treatment, prognosis | Leave a Comment »
Writing in the July issue of Genomic Medicine, Fredrik Wiklund (an expert on the genetics of prostate cancer) states that, “[R]ecent genome-wide association studies have revealed numerous genetic variants” associated with prostate cancer. He continues by stating,
Filed under: Diagnosis, Management, Prevention | Tagged: gene, genetics, risk | 4 Comments »
New data from a research team at the Institute for Cancer Research in the UK suggest that — in men and women with a faulty BRCA2 gene — the development of breast cancer and prostate cancer follows a similar pathway.
Filed under: Uncategorized | Tagged: BRCA2, gene | Leave a Comment »
According to a media release from the Prostate Cancer Foundation yesterday, research at the University of Michigan Comprehensive Cancer Center suggests that the RAF oncogene that drives fatal forms of melanoma (an aggressive type of skin cancer) may also drive aggressive forms of prostate cancer.
Filed under: Diagnosis, Drugs in development, Risk, Uncategorized | Tagged: fusion, gene, oncogene, RAF | 5 Comments »
An article in today’s Israel Herald might give you the (incorrect) idea that androgen deprivation therapy is completely inappropriate as a form of treatment for prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management | Tagged: development, fusion, gene | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site